DNA diagnostics is a technique used to detect and analyze the biological markers in the proteome and genome by applying the theory of microbiology. The utilization of this technique was initialised in early 1990’s. This technique is extensively used for detecting and testing of infectious, genetic and chronic diseases. Early disease detection and prevention becomes easy by the DNA diagnostics in order to increase the efficiency of chronic disease identification.
Some of the key factors that are driving the growth are increasing the prevalence of several types of cancers, myogenic diseases and infectious disease, acceptance or personalised medicines and improving molecular technology. In addition, increasing awareness of DNA diagnosis, continuous development of biomarkers and early stage curing of cancers are propelling growth and is expected to grow significantly over the forecast period. Furthermore, innovation in the proteomics & molecular technology, and reformed reimbursement policy is fuelling the over the past few years. However, the high cost of DNA diagnostics integration, lack of skill to handle complex & new platforms and stringent regulatory framework is restraining the growth. An increasing number of cancer patients, rapid shifting to personalised medicines from traditional diagnostics are key opportunities for players to propel expansion.
DNA diagnostics sector is segregated on the basis of its product into three types such as isolation & purification kits, software & service, instruments, and amplification kits. Owing to growing acceptance of DNA diagnosis, advanced healthcare facilities, competitive cost framework and availability of instruments have dominated the instrument segment. Software & service segment is expected to witness significant growth on account of technological advancement and rising interference of information technology over the forecast period. On the basis of technology, this sector is segmented into five technologies including mass spectrometry, DNA sequencing, PCR, in-situ hybridization, microarray and fingerprinting. Fingerprinting technology is further divided into polymerase chain reaction and fragment length polymorphism. Owing to the ability to separate and isolating property from collected samples PCR technology has the largest share.
The industry is classified on the basis of applications into disease diagnostics, paternity testing, and forensics and organ transplantation. Disease diagnostics had acquired the highest share in 2015 and is expected to grow significantly over the forecast period owing to increasing rate of infectious disease, different types of cancers and myogenic diseases. The industry is segregated into four segments on the basis of end-user applications such as self-testing or OTC, diagnostic laboratories, hospitals, the point of care and research laboratories. The hospital has acquired the maximum share of the DNA Diagnostics Market in 2015 on account of increasing use of diagnostics tests for the detection of the disease.
North America was estimated to account for the highest share in 2015, followed by Europe, Asia Pacific, and rest of the world. Owing to the presence of high technology infrastructure, investments in the development healthcare infrastructure and governments endeavour along with the high prevalence of chronic disease is propelling the growth of the North American sector. Asia Pacific is expected to experience significant growth owing to increasing funding for the healthcare infrastructure, rising population and increase in disposable income of population over the forecast period. In addition, continuous R&D activities in the DNA testing research and government initiative for the prevalence of chronic disease in this region will fuel expansion.
Some of the key players in the DNA Diagnostics Market are Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Gene-Probe Inc., Novartis, Illumina Inc., Cephide, Johnson and Johnson, Sysmex, Bio-rad laboratories, and Bayer Diagnostic. Innovative products are being introduced in the DNA Diagnostics Market as the players are launching new products. Some of the key players are also entering into collaborations, partnerships and agreements with the hospitals & laboratories to strengthen their market position, enhance the market presence and gain a competitive edge over other players.
Widespread use of these techniques in various applications along with the higher incidence rates of chronic disease and increasing awareness of personalised medicines are key trends which will be expected to fuel the growth of DNA diagnostics industry over the forecast period. The major companies such as Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Gene-Probe Inc., Novartis, Illumina Inc., Cephide, Johnson and Johnson, Sysmex, Bio-rad laboratories, and Bayer Diagnostic are expected to dominate the DNA Diagnostics Market over the forecast period owing to their continuous efforts intended to design and emphasize on new product developments to accommodate the consumer demand. This industry is expected to become highly competitive over the forecast period owing to the fact that it is driven by incorporation of new technologies and development of cost-effective products.
